GMED · Globus Medical, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $11.69B |
| P/E | 19.96 |
| Float | 133.2M |
| Beta | 0.93 |
| Volatility 30D | 41.6% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 76.9 |
| Price | 80.84 |
| Change | −7.19% |
| Prev Close | 87.10 |
| Open | 82.78 |
| Day Low | 80.91 |
| Day High | 87.38 |
| Avg Vol | 1 |
| Avg $ Vol | $95.83M |
| 52W High | 101.40 |
| 52W Low | 59.51 |
| 52W Pos | 50.9% |
| From High | −20.28% |
| From Low | +35.84% |
| Max DD 1Y | −24.26% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +2.34% |
| SMA 50 | +4.36% |
| SMA 200 | −2.98% |
| RSI (14) | 67.5 |
| Vol 90D | 38.7% |
| Vol 1Y | 46.3% |
| 1Y Range | 60–101 |
| Daily bars | 549 |
| Perf Week | +7.19% |
| Perf Month | +13.96% |
| Perf Quarter | +7.42% |
| Perf Half Y | −2.38% |
| Perf Year | +42.32% |
| Perf YTD | −7.40% |
| Prev Day | −7.19% |
| Clavix | B+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 4.26 |
| Int Cover | 45.1× |
| FCF Margin | 20.0% |
| Rev Growth | +16.6% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 25 / 49 |
Clavix risk grade
regraded every trading dayGMED grades B+, 76.9 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (57, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 25 of 49 in Health Care by Clavix score.
How rough the ride is
| GMED | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.93 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 41.6% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −24.3% | — |
| Typical daily movemedian absolute daily change | 1.26% | — |
| Days beyond ±3%of the last 252 sessions | 41 (16%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GMED | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.93 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GMED | |
|---|---|
| 1 week | +7.2% |
| 1 month | +14.0% |
| Year to date | −7.4% |
| 1 year | +42.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GMED | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 17 Aug |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 4 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| GMED | |
|---|---|
| Revenue growthyear over year | +16.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGlobus Medical is expanding the number of ExcelsiusGPS robotic systems in use through flexible leasing arrangements, shifting emphasis from upfront equipment revenue to recurring, high-margin implant sales. Following its NuVasive integration, the company reported a 35.4% adjusted profit margin before interest, taxes, depreciation and amortization, while free cash flow nearly doubled year over year and ExcelsiusGPS placements rose 25% despite a segment revenue decline.
Globus Medical shares recently closed at US$81.26. No specific catalyst was identified.
Seventeen analyst firms cover Globus Medical and collectively rate the stock “Moderate Buy,” with an average target price, the share price analysts expect, of $99.46. Nine rate it “buy,” five rate it “hold,” and three reportedly issue a “strong buy.”
Globus Medical used the 41st Annual North American Spine Society Meeting to showcase SCRIPT, an FDA-cleared patient-specific spinal implant platform, and its XLIF Prone Procedural Solution, which pairs a new patient positioner with the MaXcess Air retractor. The company is tying these implants into its ExcelsiusGPS and ExcelsiusHub surgical robotics systems.
Globus Medical unveiled its SCRIPT custom-fit spinal implant system at the NASS 2026 spine surgery conference after receiving FDA clearance, and also presented its XLIF Prone system for lateral spine surgery performed with patients lying face-down.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ALGN | Align Technology, Inc. | B | $11.71B | 27.75 | 1.72 | Compare |
| MOH | Molina Healthcare Inc | B | $11.82B | 22.99 | 0.69 | Compare |
| PODD | Insulet Corporation | B- | $11.44B | 28.61 | 1.08 | Compare |
| DVA | DaVita Inc | B | $12.12B | 12.75 | 0.82 | Compare |
| COO | The Cooper Companies, Inc. | B | $12.25B | 20.28 | 0.79 | Compare |
| PEN | Penumbra, Inc. | A+ | $12.71B | 79.35 | 0.65 | Compare |
| UHS | Universal Health Services, Inc. | A- | $10.47B | 7.56 | 1.10 | Compare |
| BAX | Baxter International Inc. | B | $13.71B | — | 0.62 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.